SCHEMBL1421808

SCHEMBL1421808

O=C(O)c1cccc(CI)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.66
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
HIF1A Q16665 1/20 0.53
ANPEP P15144 1/20 0.53
ENPEP Q07075 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA6 P23280 1/20 0.52
CA9 Q16790 1/20 0.52
MEP1B Q16820 2/20 0.51
NR4A2 P43354 1/20 0.51
KMT2A Q03164 1/20 0.51
MRGPRX4 Q96LA9 3/20 0.50
MEP1A Q16819 1/20 0.50
TP53 P04637 1/20 0.50
PKM P14618 1/20 0.50
NFKB1 P19838 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27705268 0.93 FOLH1 (0.58) FOLH1CYP2D6CYP2C9HIF1AANPEP
Isobutane SCHEMBL3663817 0.93 FOLH1 (0.58) FOLH1ANPEPENPEPMEP1BMRGPRX4
SCHEMBL27705284 0.87 FOLH1 (0.56) FOLH1CYP2D6CYP2C9HIF1AANPEP
SCHEMBL1777321 0.85 FOLH1 (0.68) FOLH1CYP2D6CYP2C9HIF1AANPEP
SCHEMBL20880892 0.84 L3MBTL1 (0.63) FOLH1HIF1ARAB9ASMN1; SMN2
SCHEMBL1541757 0.84 FOLH1 (0.61) FOLH1CYP2D6CYP2C9HIF1AANPEP
SCHEMBL371526 0.83 FOLH1 (0.70) FOLH1CYP2D6CYP2C9HIF1AANPEP
SCHEMBL30791058 0.83 FOLH1 (0.70) FOLH1CYP2D6CYP2C9HIF1AANPEP
SCHEMBL70351 0.83 FOLH1 (0.70) FOLH1CYP2D6CYP2C9HIF1AANPEP
SCHEMBL20109815 0.82 PARP1 (0.53) FOLH1MEP1BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109810067-A A kind of preparation method of Su Woleisheng intermediate 扬子江药业集团有限公司 2019-05-28 CN claimed
CN-114656461-B Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and synthetic method and application thereof 浙江工业大学 2024-01-30 CN disclosed
CN-105308048-B Substituted 2-azabicyclic compounds and their use as orexin receptor modulators 詹森药业有限公司 2019-10-08 CN disclosed
CN-106349228-B Substituted quianzolinones and its preparation method and application 广东东阳光药业有限公司 2019-07-09 CN disclosed
CN-105461699-B Substituted heterocyclic compound and its application method and purposes 广东东阳光药业有限公司 2019-07-09 CN disclosed
CN-107207516-B Octahydro pyrrolo- [3,4-c] azole derivatives and application thereof 广东东阳光药业有限公司 2019-06-25 CN disclosed
CN-109810067-A A kind of preparation method of Su Woleisheng intermediate 扬子江药业集团有限公司 2019-05-28 CN disclosed
EP-2945619-B1 CRYSTALLINE FORM OF VSN16 UCL BUSINESS PLC (GB) 2019-05-08 EP disclosed
CN-106674207-B Substituted aryl heteroaryl compound and application thereof 广东东阳光药业有限公司 2019-04-19 CN disclosed
CN-106164047-B 1,2- substituted cyclopentane as orexin receptor antagonists 武田药品工业株式会社 2019-04-16 CN disclosed
US-20080108662-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR CHU CHANG A 2008-05-08 US disclosed
US-7355049-B2 Biaryloxymethylarenecarboxylic acids as glycogen synthase activator HOFFMANN-LA ROCHE INC. (US) 2008-04-08 US disclosed
EP-1745011-A2 MODULATORS OF CANNABINOID RECEPTORS UCL Biomedica plc (GB) 2007-01-24 EP disclosed
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GILLESPIE PAUL 2006-06-08 US disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
WO-2005080316-A2 MODULATORS OF CANNABINOID RECEPTORS UCL BIOMEDICA PLC. (GB) 2005-09-01 WO disclosed
EP-1404652-A4 A NOVEL ALKALOID DERIVATIVE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME CHEMTECH RES INC (KR) 2005-06-15 EP disclosed
EP-1404652-A1 A NOVEL ALKALOID DERIVATIVE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Chemtech Research Incorporation (KR) 2004-04-07 EP disclosed
WO-2002100824-A1 A NOVEL ALKALOID DERIVATIVE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME CHEMTECH RESEARCH INCORPORATION (KR) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R FOLH1 3714/4885CYP2D6 2165/4885CYP2C9 1342/4885
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GYS2, GYS1, GSK3A FOLH1 2704/4885CYP2D6 460/4885CYP2C9 415/4885
US-20080108662-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR GYS2, PYGL, GYS1 FOLH1 2925/4885CYP2D6 461/4885CYP2C9 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.